Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Accumulated Depreciation & Amortization (2016 - 2023)

Historic Accumulated Depreciation & Amortization for Spyre Therapeutics (SYRE) over the last 9 years, with Q4 2023 value amounting to $744000.0.

  • Spyre Therapeutics' Accumulated Depreciation & Amortization fell 5252.07% to $744000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $744000.0, marking a year-over-year decrease of 5252.07%. This contributed to the annual value of $744000.0 for FY2023, which is 5252.07% down from last year.
  • Spyre Therapeutics' Accumulated Depreciation & Amortization amounted to $744000.0 in Q4 2023, which was down 5252.07% from $1.6 million recorded in Q4 2022.
  • In the past 5 years, Spyre Therapeutics' Accumulated Depreciation & Amortization registered a high of $2.0 million during Q4 2020, and its lowest value of $744000.0 during Q4 2023.
  • Over the past 5 years, Spyre Therapeutics' median Accumulated Depreciation & Amortization value was $1.6 million (recorded in 2022), while the average stood at $1.4 million.
  • As far as peak fluctuations go, Spyre Therapeutics' Accumulated Depreciation & Amortization skyrocketed by 8796.21% in 2020, and later tumbled by 5252.07% in 2023.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Accumulated Depreciation & Amortization stood at $1.1 million in 2019, then surged by 87.96% to $2.0 million in 2020, then dropped by 20.52% to $1.6 million in 2021, then fell by 0.57% to $1.6 million in 2022, then crashed by 52.52% to $744000.0 in 2023.
  • Its Accumulated Depreciation & Amortization was $744000.0 in Q4 2023, compared to $1.6 million in Q4 2022 and $1.6 million in Q4 2021.